Conmed (CNMD) Cost of Revenue (2010 - 2026)

Conmed's Cost of Revenue history runs 17 years deep, the most recent figure standing at $133.6 million for Q1 2026.

• Quarterly Cost of Revenue fell 6.9% year-over-year to $133.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $614.3 million (up 6.44% YoY) and the FY2025 annual result came in at $624.2 million, up 8.76% from the prior year.
• Cost of Revenue was $133.6 million for Q1 2026 at Conmed, down from $154.9 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $171.8 million in Q3 2025 and bottomed at $106.3 million in Q1 2022.
• A 5-year average of $139.7 million and a median of $140.3 million in 2024 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2023 — Cost of Revenue surged 31.8% — and 2026, when it fell 6.9%.
• Conmed's Cost of Revenue stood at $119.0 million in 2022, then gained by 21.73% to $144.9 million in 2023, then advanced by 1.88% to $147.6 million in 2024, then climbed by 4.95% to $154.9 million in 2025, then slipped by 13.76% to $133.6 million in 2026.
• Business Quant data shows CNMD's Cost of Revenue at $133.6 million in Q1 2026, $154.9 million in Q4 2025, and $171.8 million in Q3 2025.